CHICAGO--(BUSINESS WIRE)--Link to Fitch Ratings' Report: Global Pharmaceutical R&D Pipeline (Advancing Cancer Therapies)
Biologics will play an increasing role in global drug development as the number of new molecular entities (NMEs) increases, according to a new Fitch Ratings report.
The numbers of NME approvals in 2014 through the end of May were up compared to the prior year five-month period in 2013. The FDA cleared 16 novel medicines for U.S. marketing during the first five months of 2014 compared to 14 in 2013. Interestingly, six biologics were approved in the 2014 period, while only one was approved in the 2013 period.
The full report 'Global Pharmaceutical R&D Pipeline' is available at 'www.fitchratings.com.' The report provides full R&D data for all of the major global pharmaceutical companies.
Additional information is available at 'www.fitchratings.com'.